{"id":"allogeneic-mesenchymal-precursor-cells","_chembl":{"chemblId":"CHEMBL5315108","moleculeType":"Unknown"},"modality":"Small molecule","_dailymed":null,"mechanism":{"explanation":"These cells secrete anti-inflammatory cytokines and growth factors that modulate immune cell function, reduce pro-inflammatory signaling, and promote tissue repair. They interact with immune cells to suppress excessive inflammatory responses without broadly suppressing the immune system.","oneSentence":"Mesenchymal precursor cells modulate immune responses and reduce inflammation through paracrine signaling and cell-to-cell interactions."},"_scrapedAt":"2026-03-28T03:21:22.755Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123082,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"Remestemcel-L","brand":"Ryoncil","company":"Mesoblast","rationale":"Allogeneic mesenchymal stromal cells for steroid-refractory acute GVHD"},{"name":"Darvadstrocel","brand":"Alofisel","company":"Takeda","rationale":"Allogeneic adipose-derived mesenchymal stem cells for fistulizing Crohn's"}],"description":"Allogeneic mesenchymal precursor cells are an investigational cell therapy developed by Mesoblast for inflammatory and immune-mediated conditions. These cells are derived from healthy donor bone marrow and expanded in culture to produce off-the-shelf cellular products for potential treatment of various diseases.","indications":{"approved":[{"status":"investigational","condition":"Chronic low back pain due to degenerative disc disease","patientPopulation":"Adult patients with chronic low back pain"},{"status":"investigational","condition":"Chronic heart failure","patientPopulation":"Adult patients with chronic heart failure"},{"status":"investigational","condition":"Acute graft versus host disease","patientPopulation":"Pediatric patients with steroid-refractory acute GVHD"}]},"trialDetails":[{"nctId":"NCT02032004","phase":"PHASE3","title":"Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2014-03-03","conditions":"Chronic Heart Failure","enrollment":565},{"nctId":"NCT03079401","phase":"PHASE1, PHASE2","title":"Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle","status":"UNKNOWN","sponsor":"Boston Children's Hospital","startDate":"2017-11-27","conditions":"Hypoplastic Left Heart Syndrome, Atrioventricular Canal","enrollment":19},{"nctId":"NCT02412735","phase":"PHASE3","title":"Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain","status":"COMPLETED","sponsor":"Mesoblast, Ltd.","startDate":"2015-03-06","conditions":"Degenerative Disc Disease","enrollment":404},{"nctId":"NCT01781390","phase":"PHASE2","title":"Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2013-03-11","conditions":"Acute Myocardial Infarction","enrollment":106},{"nctId":"NCT01290367","phase":"PHASE2","title":"Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain","status":"COMPLETED","sponsor":"Mesoblast, Ltd.","startDate":"2011-08","conditions":"Degenerative Disc Disease","enrollment":100},{"nctId":"NCT01851070","phase":"PHASE2","title":"A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor","status":"COMPLETED","sponsor":"Mesoblast, Ltd.","startDate":"2013-07","conditions":"Rheumatoid Arthritis","enrollment":48},{"nctId":"NCT01576328","phase":"PHASE1, PHASE2","title":"Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes","status":"COMPLETED","sponsor":"Mesoblast, Ltd.","startDate":"2012-04","conditions":"Type 2 Diabetes","enrollment":61},{"nctId":"NCT00721045","phase":"PHASE2","title":"A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure","status":"COMPLETED","sponsor":"Mesoblast, Ltd.","startDate":"2008-08","conditions":"Heart Failure","enrollment":60},{"nctId":"NCT01753440","phase":"PHASE2","title":"Allogeneic Stem Cells Implantation Combined With Coronary Bypass Grafting in Patients With Ischemic Cardiomyopathy","status":"COMPLETED","sponsor":"AHEPA University Hospital","startDate":"2012-11","conditions":"Coronary Artery Disease, Ischemic Cardiomyopathy","enrollment":11},{"nctId":"NCT01843387","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy","status":"COMPLETED","sponsor":"Mesoblast, Ltd.","startDate":"2013-07","conditions":"Diabetic Nephropathy, Type 2 Diabetes","enrollment":30},{"nctId":"NCT00555828","phase":"PHASE1, PHASE2","title":"Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"Angioblast Systems","startDate":"2008-03","conditions":"Myocardial Infarction","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Allogeneic Mesenchymal Precursor Cells","genericName":"Allogeneic Mesenchymal Precursor Cells","companyName":"Mesoblast, Ltd.","companyId":"mesoblast-ltd","firstApprovalDate":"","aiSummary":"Allogeneic Mesenchymal Precursor Cells are a type of somatic cell supplemental therapy used to treat various conditions, including Hypoplastic Left Heart Syndrome, Atrioventricular Canal, Rheumatoid Arthritis, Coronary Artery Disease, and Ischemic Cardiomyopathy. The exact mechanism of action of Allogeneic Mesenchymal Precursor Cells is currently unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}